MaxCyte (MXCT)
(Delayed Data from NSDQ)
$3.81 USD
-0.09 (-2.31%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $3.80 -0.01 (-0.26%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for MaxCyte, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 41 | 44 | 34 | 26 | 22 |
Cost Of Goods | 5 | 5 | 4 | 3 | 3 |
Gross Profit | 37 | 39 | 30 | 23 | 19 |
Selling & Adminstrative & Depr. & Amort Expenses | 85 | 67 | 48 | 34 | 32 |
Income After Depreciation & Amortization | -48 | -27 | -18 | -11 | -12 |
Non-Operating Income | 10 | 4 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 1 | 1 | 1 |
Pretax Income | -38 | -24 | -19 | -12 | -13 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -38 | -24 | -19 | -12 | -13 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -38 | -24 | -19 | -12 | -13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -51 | -27 | -17 | -10 | -12 |
Depreciation & Amortization (Cash Flow) | -3 | 0 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -48 | -27 | -18 | -11 | -12 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 103.27 | 101.70 | 90.62 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.37 | -0.23 | -0.21 | NA | NA |
Diluted Net EPS (GAAP) | -0.37 | -0.23 | -0.21 | -0.17 | NA |
Fiscal Year end for MaxCyte, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 10.43 | 11.34 | 15.66 | 8.00 | 9.04 |
Cost Of Goods | 1.49 | 1.40 | 1.57 | 0.79 | 1.38 |
Gross Profit | 8.94 | 9.94 | 14.09 | 7.21 | 7.67 |
SG&A, R&D, and Dept/Amort Expenses | 20.91 | 22.22 | 22.18 | 21.16 | 20.74 |
Income After SG&A, R&D, and Dept/Amort Expenses | -11.97 | -12.28 | -8.09 | -13.95 | -13.07 |
Non-Operating Income | 2.59 | 2.75 | 2.82 | 2.70 | 2.56 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -9.38 | -9.53 | -5.28 | -11.25 | -10.51 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -9.38 | -9.53 | -5.28 | -11.25 | -10.51 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -9.38 | -9.53 | -5.28 | -11.25 | -10.51 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 104.64 | 104.09 | 103.70 | 103.45 | 103.06 |
Diluted EPS Before Non-Recurring Items | -0.09 | -0.09 | -0.05 | -0.11 | -0.10 |
Diluted Net EPS (GAAP) | -0.09 | -0.09 | -0.05 | -0.11 | -0.10 |